Key Highlights

  • 4basebio signed a clinical Supply agreement worth an approximate seven-figure sum with an undisclosed cancer immunotherapy developer.
  • FY2025 Revenue rose 81% to £1.7 million, though the net loss widened to £16.9 million from £12.3 million.
  • Cash fell to £17.8 million at year-end from £34.6 million as the company invested in Manufacturing capacity.
  • The company received its MHRA GMP manufacturing licence in April 2025 and is building a new Cambridge manufacturing hub.
  • An existing Tier 1 pharmaceutical partner is now dosing patients in a Phase I/II US trial using 4basebio's opDNA technology.

The Cambridge-based LSE biotech has signed a clinical supply agreement worth a seven-figure sum with a cancer immunotherapy developer, arriving alongside full-year results that show revenue up 81% but losses widening as it builds out manufacturing capacity.

4basebio (LSE:4BB) is a small but increasingly active Cambridge biotech making synthetic DNA and non-viral delivery technology for gene therapies, mRNA vaccines and genome editing. On 20 May 2026 it disclosed a new clinical supply agreement with an unnamed cancer immunotherapy developer worth an approximate seven-figure sum over 12 months, published the same day as its results for the year to 31 December 2025. Together the two announcements offer the clearest picture yet of a company converting years of platform development into recurring commercial revenue.

What Happened

4basebio said it had signed an agreement to supply GMP-grade opDNA®, its proprietary synthetic DNA template, as a critical starting material for a client's immunotherapy candidate ahead of an upcoming Phase II trial. It described the partner only as "a leading cancer immunotherapy innovator" and did not name the indication, citing client confidentiality. Chief executive Dr Amy Walker said the Partnership "demonstrates how our proprietary DNA technology platform can help clients overcome complex manufacturing hurdles and bring safer and effective therapies to patients." The arrangement is expected to generate an approximate seven-figure revenue stream over the next 12 months. Management cited opDNA's safety case relative to conventional plasmid DNA — eliminating microbial contamination risk and antibiotic-resistance genes — alongside its potential to shorten development timelines from sequence to clinic.

Why It Matters

The deal matters because it is a paying, near-term contract rather than a research collaboration, and it sits in oncology, an area 4basebio had not previously highlighted alongside its mRNA Vaccine and gene-therapy work. It follows a separate, longer-running relationship: in October 2025 the company confirmed a "global Tier 1 pharmaceutical partner" had begun dosing patients in a Phase I/II US clinical trial using an mRNA therapeutic built on its opDNA template, after securing FDA Investigational New Drug approval — a relationship tracing back to a supply agreement signed in April 2024. Together, the disclosures suggest 4basebio's synthetic DNA is now embedded in more than one clinical-stage pipeline held by third parties, the validation stage small-cap life-science suppliers need before they can point to durable, repeatable revenue.

Latest Financial and Operational Performance

4basebio's final results for the year ended 31 December 2025 showed revenue of £1.7m, up 81% from £0.9m, with clinical-stage revenue roughly doubling to £1.1m and DNA product sales up 100%. Gross Profit rose to £0.974m from £0.630m. Losses widened considerably, though: the operating loss grew to £17.6m from £12.0m and the net loss to £16.9m from £12.3m, driven by administrative expenses rising to £17.7m from £13.9m as the company built out its commercial team and manufacturing capability. Cash fell to £17.8m at year-end from £34.6m, while net Assets fell to £10.1m from £26.4m. Chief executive Dr Amy Walker said 2025 "represented a step-change for the Company, with GMP accreditation, a growing customer base and commercial appointments underpinning our transition into a highly commercially focused Business ," while flagging that some client mRNA vaccine programmes originally expected to start in 2025 may be deferred. Cash, including a €7m drawdown from Deutsche Balaton in April 2026, funds the company into late 2027.

Key Numbers

  • FY2025 revenue: £1.7m, up 81% (FY2024: £0.9m)
  • FY2025 operating loss: £17.6m (FY2024: £12.0m)
  • FY2025 net loss: £16.9m (FY2024: £12.3m)
  • Cash at 31 December 2025: £17.8m (31 December 2024: £34.6m)
  • Net assets at 31 December 2025: £10.1m (31 December 2024: £26.4m)
  • Oncology supply deal announced 20 May 2026: approximate seven-figure revenue over 12 months
  • Share price, 7 August 2026: c.520p; Market Capitalisation roughly £81m
  • Existing Tier 1 pharma supply deal (signed April 2024) now dosing patients in a Phase I/II US trial

Growth Opportunities

The clearest near-term driver is converting the pipeline of client programmes into paying supply contracts as more reach clinical stages requiring GMP-grade material. The company received its MHRA GMP manufacturing licence in April 2025, a prerequisite for supplying regulated trials, and has since added capacity: in March 2026 it signed a Lease on a 26,500 sq ft manufacturing hub in Bar Hill, Cambridge, including 7,500 sq ft of laboratory space across 15 labs, expected operational in late summer 2026. In May 2026 it also launched a high-capacity enzymatic single-stranded DNA (ssDNA) product line, widening its applications beyond opDNA. Leadership has been refreshed too, with Dr Amy Walker succeeding founder Dr Heikki Lanckriet as CEO in February 2026, followed by Christine Wolosin's promotion to Chief Commercial Officer, Scott Lorimer's appointment as Chief Operating Officer, and a new Chief Financial Officer in May 2026 — a build-out the company frames as sharpening its commercial focus.

Risks Investors Should Know

4basebio remains a pre-profit, cash-consuming business: net losses grew sharply year-on-year, cash reserves more than halved over 2025, and admin costs rose faster than revenue as it invested ahead of Demand . Management's own commentary acknowledges client programmes can slip, with some expected 2025 mRNA vaccine starts already deferred — a reminder that revenue visibility depends on third-party timelines it does not control. Both the oncology deal and the Tier 1 pharma relationship remain undisclosed as to partner identity and indication, limiting investors' ability to verify programme progress independently. The extra funding drawn in April 2026 and the scale of the new Cambridge lease point to ongoing capital intensity, and further fundraising cannot be ruled out if revenue growth does not keep pace with cash burn.

What to Watch Next

Watch for further supply-agreement announcements as the Bar Hill Facility comes online, progress updates on the Phase I/II mRNA trial and the new Phase II oncology programme, and half-year results, likely due around September 2026, confirming whether 2026 revenue growth is tracking management's guidance for a significant step-up.

Outlook

4basebio's May 2026 announcements show a company generating real, if still modest, commercial traction from its synthetic DNA platform, with a second seven-figure supply agreement adding to an existing pharma relationship already in Clinical Trials . That progress has come at a cost, with losses and cash burn both rising sharply in 2025 as the company built capacity ahead of revenue. Whether 4basebio can convert its pipeline of undisclosed partner programmes into Recurring Revenue at a scale that closes that gap, without relying indefinitely on external funding, is the central question for investors through the rest of 2026.